Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
October 21, 2023 07:30 ET
|
ORIC Pharmaceuticals
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases ...
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
October 17, 2023 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
August 30, 2023 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023 16:05 ET
|
ORIC Pharmaceuticals
Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023 Initial Phase 1b clinical data expected for ORIC-533...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
June 26, 2023 08:30 ET
|
ORIC Pharmaceuticals
Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital Pro forma cash and investments expected to fund...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023 16:15 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...